MedTrace Logo

Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections (DALBADIA)

NCT04959799 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98

Last updated 2022-09-21

No results posted yet for this study

Summary

The study aims to describe the current use of dalbavancin among diabetic patients with infections in a real-world clinical setting in Italy and Spain.

Conditions

Interventions

DRUG

Dalbavancin

Adult diabetic patients suffering from infections who received the last dose of dalbavancin according to the current standard clinical practice at least 30 (+7) days before enrolment in the study.

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Aziende Chimiche Riunite Angelini Francesco S.p.A

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-02
Primary Completion
2022-05-31
Completion
2022-05-31

Countries

  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04959799 on ClinicalTrials.gov